AI-native deal intelligence

Read the science, not just the pitch deck.

Locus is an AI agent that autonomously scouts biotech startups by evaluating their research, patents, and clinical data. The PhD analyst that never sleeps.

4,400+ AI deals in Q3 2025
75% of VCs use AI in reviews
0 read the actual science

Biotech due diligence was built for a world without AI.

Your analysts spend weeks reading preprints, cross-referencing patents, and evaluating mechanism-of-action novelty. General VC tools track financials and founder LinkedIn profiles. Nobody reads the biology.

Today's Tools

  • PitchBook tracks funding rounds, not science
  • CB Insights scores momentum, not mechanism
  • PhD analysts take 2-3 weeks per deep dive
  • Deals found after they've already raised

With Locus

  • Reads bioRxiv and medRxiv preprints daily
  • Evaluates clinical trial design and IP strength
  • Generates deal signals in hours, not weeks
  • Finds companies before they hit the radar

An AI analyst with a molecular genetics degree.

🧬

Preprint Monitoring

Continuously scans bioRxiv, medRxiv, and patent databases. Identifies novel research with commercial potential and maps it to startup activity.

🔍

Scientific Due Diligence

Evaluates mechanism-of-action novelty, clinical trial design quality, IP defensibility, and competitive positioning in the therapeutic landscape.

📋

Autonomous Deal Memos

Generates investment-ready deal memos with scientific assessment, market sizing, competitive analysis, and risk evaluation. Ready for your IC meeting.

📡

Portfolio Intelligence

Monitors your existing portfolio companies for new publications, patent filings, clinical trial updates, and competitive threats. Alerts when action is needed.

Every great biotech investment
starts with the science.

Locus exists because the best deals aren't found in databases. They're buried in preprints, patent applications, and clinical trial registries. We read what others can't.